Management of Chronic Hepatitis B with Nucleoside or Nucleotide Analogues: A Review of Current Guidelines
2
조회
0
다운로드
1
인용
0
참고문헌
초록
Antiviral treatment of hepatitis B is one of the most rapidly evolving fields in current medicine. Guidelines for the management of chronic hepatitis B (CH-B)have been proposed and revised by many academic societies and groups. Recommendations for nucleoside or nucleotide analogue (NUC) therapy from representative current guidelines are compared herein with each other and with previous guidelines. Several differences among individual recommendations may reflect regional and temporal differences as well as differences in the available data upon which the guidelines are based. Nevertheless, these guidelines share a common principle regarding NUC treatment for CH-B: long-term viral suppression by the drugs with potent antiviral activity and low rate of development of drug resistance to prevent disease progression. A review of the past and current guidelines for the management of CH-B would be useful for evaluating the current status of management of the disease and to identify better solutions for improving the outcome of patients with CH-B.
Abstract
Antiviral treatment of hepatitis B is one of the most rapidly evolving fields in current medicine. Guidelines for the management of chronic hepatitis B (CH-B)have been proposed and revised by many academic societies and groups. Recommendations for nucleoside or nucleotide analogue (NUC) therapy from representative current guidelines are compared herein with each other and with previous guidelines. Several differences among individual recommendations may reflect regional and temporal differences as well as differences in the available data upon which the guidelines are based. Nevertheless, these guidelines share a common principle regarding NUC treatment for CH-B: long-term viral suppression by the drugs with potent antiviral activity and low rate of development of drug resistance to prevent disease progression. A review of the past and current guidelines for the management of CH-B would be useful for evaluating the current status of management of the disease and to identify better solutions for improving the outcome of patients with CH-B.
참고문헌 (32)
- Lok AS, "Management of hepatitis B: 2000: summary of a workshop", Gastroenterology, 120, pp.1828~1853 (2001)
- "Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region: Core Working Party for Asia-Pacific Consensus on Hepatitis B and C", J Gastroenterol Hepatol, 15, pp.825~841 (2000)
- Lok AS, "Chronic hepatitis B", Hepatology, 34, pp.1225~1241 (2001)
- Lee KS, "Management of chronic hepatitis B", Korean J Hepatol, 13, pp.447~488 (2007)
- Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B: a2008 update", Hepatol Int, 2, pp.263~283 (2008)
- Keeffe EB, "A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update", Clin Gastroenterol Hepatol, 6, pp.1315~1341 (2008)
- European Association for the Study of the Liver, "EASL Clinical Practice Guidelines: management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load", Gastroenterology, 130, pp.678~686 (2006)
- Chu CJ, "Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection", Hepatology, 36, pp.1408~1415 (2002)
- Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
- Yuen MF, "Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications", Gut, 54, pp.1610~1614 (2005)
- Kim HC, "Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study", BMJ, 328, pp.983~ (2004)
- Prati D, "Updated definitions of healthy ranges for serum alanine aminotransferase levels", Ann Intern Med, 137, pp.1~10 (2002)
- Lai CL, "The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points", Ann Intern Med, 147, pp.58~61 (2007)
- Rockey DC, "Liver biopsy", Hepatology, 49, pp.1017~1044 (2009)
- Lai M, "The clinical significance of persistently normal ALT in chronic hepatitis B infection", J Hepatol, 47, pp.760~767 (2007)
- Yoo BC, "Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B", Hepatology, 45, pp.1172~1178 (2007)
- Yoo BC, "Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression", Hepatology, 46, pp.1041~1048 (2007)
- Marcellin P, "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B", N Engl J Med, 359, pp.2442~2455 (2008)
- Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
- Gish RG, "Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B", Gastroenterology, 133, pp.1437~1444 (2007)
- Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
- Yuen MF, "Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy", Hepatology, 34, pp.785~791 (2001)
- Keeffe EB, "Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B", Clin Gastroenterol Hepatol, 5, pp.890~897 (2007)
- Peters MG, "Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B", Gastroenterology, 126, pp.91~101 (2004)
- Lampertico P, "Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients", Gastroenterology, 133, pp.1445~1451 (2007)
- Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B", Hepatology, 45, pp.307~313 (2007)
- Sherman M, "Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks", Hepatology, 48, pp.99~108 (2008)
- Ono SK, "The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance", J Clin Invest, 107, pp.449~455 (2001)
- van Bommel F, "Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection", Hepatology, 40, pp.1421~1425 (2004)
- Fung SK, "Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation", J Hepatol, 43, pp.937~943 (2005)